| Primary information |
|---|
| ThPP ID | Th1198 |
| Therapeutic Peptide/Protein Name | Sacrosidase |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | 100000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet; therefore, sacrosidase offers a potential alternative for symptom relief. |
| Indication/Disease | For the treatment of congenital sucrose-isomaltase deficiency (CSID). |
| Pharmacodynamics | Sucrase is naturally produced in the brush border of the small intestine, primarily the distal duodenum and jejunum. Sucrase hydrolyzes the disaccharide sucrose into its component monosaccharides, glucose and fructose. Isomaltase breaks down disaccharides from starch into simple sugars. SUCRAID does not contain isomaltase. |
| Mechanism of Action | Sacrosidase is a [beta]-fructofuranoside fructohydrolase that hydrolyzes sucrose. Unlike human intestinal sucrase-isomaltase, it has no activity with oligosaccharides containing 1,6 glucosyl bonds. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | It has been suggested that sucrose is better absorbed (and sacrosidase activity preserved) when patients were given milk before sacrosidase rather than consuming the enzyme product alone. Therefore, it has been recommended to take half dose of sacrosidase just after a protein-containing meal, and the other half of the dose approximately half-way through the meal. |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | Enzymes |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market |
|---|
| Brand Name | Sucraid |
| Company | QOL Medical, LLC |
| Brand Discription | SUCRAID® (sacrosidase) oral solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). |
| Prescribed for | NA |
| Chemical Name | ß,D-fructofuranoside fructohydrolase |
| Formulation | NA |
| Physcial Appearnce | Solution |
| Route of Administration | Oral |
| Recommended Dosage | The recommended dosage is 1 or 2 mL (8,500 to 17,000 I.U.) or 1 or 2 full measuring scoops (each full measuring scoop equals 1mL; 28 drops from the SUCRAID container tip equals 1mL) taken orally with each meal or snack diluted with 2 to 4 ounces of water, milk or infant formula. The beverage or infant formula should be served cold or at room temperature. The beverage or infant formula should not be warmed or heated before or after addition of SUCRAID because heating is likely to decrease potency. SUCRAID should not be reconstituted or consumed with fruit juice since its acidity may reduce the enzyme activity. It is recommended that approximately half of the dosage be taken at the beginning of the meal or snack and the remainder be taken during the meal or snack. |
| Contraindication | Patients known to be hypersensitive to yeast, yeast products, glycerin (glycerol), or papain. |
| Side Effects | Abdominal pain, vomiting; nausea; diarrhea; constipation; insomnia; headache; nervousness and dehydration. |
| Useful Link | http://www.rxlist.com/sucraid-drug.htm |
| PubMed ID | 26163121, 19680155, 19330928, 11794951, 10576960, 9932843 |
| 3-D Structure | N.A. |